Prospects for Lentiviral Vector Mediated Prostaglandin F Synthase Gene Delivery in Monkey Eyes In vivo

References

• National Eye Institute. Glaucoma and optic neuropathies program. Maryland: National Plan for Eye and Vision Research; 2006
   Google Scholar
• Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog Retin Eye Res 2005;245:612–637
   Google Scholar
• VanVeldhuuisen PC, Ederer F, Gaasterland DE, Sullivan EK, Beck A, Prum Jr. BE, et al. The advanced glaucoma intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;1304:429–440
   Google Scholar
• Anderson DR. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol 2003;142:86–90
   Google Scholar
• Toris CB, Gabelt BT, Kaufman PL. Update on the effects of topical prostaglandins on aqueous humor dynamics. Surv Ophthalmol 2008;53:S107–S120
   PubMed Web of Science ®Google Scholar
• Crawford KS, Kaufman PL. Dose-related effects of prostaglandin F2a isopropylester on intraocular pressure, refraction and pupil diameter in monkeys. Invest Ophthalmol Vis Sci 1991;32:510–519
   PubMedGoogle Scholar
• Nilsson SFE, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2a-1-isopropylester in the cynomolgus monkey. Exp Eye Res 1989;48:707–716
   PubMed Web of Science ®Google Scholar
• Gabelt BT, Kaufman PL. Prostaglandin F2a increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989;49:389–402
   PubMed Web of Science ®Google Scholar
• Crawford K, Kaufman PL, Gabelt BT. Effects of topical PGF2a on aqueous humor dynamics in cynomolgus monkeys. Curr Eye Res 1987;6:1035–1044
   PubMed Web of Science ®Google Scholar
• Gabelt BT, Kaufman PL. The effect of prostaglandin F2a on trabecular outflow facility in cynomolgus monkeys. Exp Eye Res 1990;51:87–91
   PubMed Web of Science ®Google Scholar
• Hayashi M, Yablonski ME, Bito LZ. Eicosanoids as a new class of ocular hypotensive agents. 2. Comparison of the apparent mechanism of the ocular hypotensive effects of A and F type prostaglandins. Invest Ophthalmol Vis Sci 1987;28:1639–1643
   PubMed Web of Science ®Google Scholar
• Ocklind A, Lake S, Wentzel P, Nistér M, Stjernschantz J. Localization of the prostaglandin F2a receptor messenger RNA and protein in the cynomolgus monkey eye. Invest Ophthalmol Vis Sci 1996;37:716–726
   PubMed Web of Science ®Google Scholar
• Poyer JF, Millar JC, Kaufman PL. Prostaglandin F2a effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci 1995;36:2461–2465
   PubMed Web of Science ®Google Scholar
• van Alphen GWHM, Robinette SL, Macri FJ. Drug effects on ciliary muscle and choroid preparations in vitro. Arch Ophthalmol 1962;68:111–123
   Google Scholar
• Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN. Topical prostaglandin F2a treatment reduces collagen types I, III and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 1999;117:794–801
   PubMed Web of Science ®Google Scholar
• Lindsey JD, Kashiwagi K, Boyle D, Kashiwagi F, Firestein GS, Weinreb RN. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res 1996;15:869–875
   PubMed Web of Science ®Google Scholar
• Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism – implications for uveoscleral outflow. Surv Ophthalmol 1997;41(Suppl 2):S53–S59
   Google Scholar
• Weinreb RN. Enhancement of scleral macromolecular permeability with prostaglandins. Trans Am Ophthmol Soc 2001;99:319–343
   PubMedGoogle Scholar
• Kim J-W, Lindsey JD, Wang N, Weinreb RN. Increased human scleral permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci 2001;42:1514–1521
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Lindsey JD, Marchenko G, Marchenko N, Angert M, Strongin A. Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest Ophthalmol Vis Sci 2004;4512:4368–4377
   Google Scholar
• Biswas S, Bhattacherjee P, Paterson CA. Prostaglandin E2 receptor subtypes, EP1, EP2, EP3 and EP4 in human and mouse ocular tissues – a comparative immunohistochemical study. Prostagladins Leukot Essent Fatty Acids 2004;715:277–288
   Google Scholar
• Nilsson SF, Drecoll E, Lutjen-Drecoll E, Toris CB, Krauss AH, Kharlamb A, et al. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest Ophthalmol Vis Sci 2006;479:4042–4049
   Google Scholar
• Gabelt BT, Hennes EA, Bendel MA, Constant CE, Okka M, Kaufman PL. Prostaglandin subtype-selective and non-selective IOP lowering comparison in monkeys. J Ocul Pharmacol 2009;25:1–8
   Google Scholar
• Richter M, Krauss AH-P, Woodward DF, Lutjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci 2003;44:4419–4426
   PubMed Web of Science ®Google Scholar
• Yücel YH, Johnston MG, Ly T, Patel M, Drake B, Gümüs E, et al. Identification of lymphatics in the ciliary body of the human eye: a novel “uveolymphatic” outflow pathway. Exp Eye Res 2009;895:810–819
   Google Scholar
• Kim M, Johnston MG, Gupta N, Moore S, Yücel YH. A model to measure lymphatic drainage from the eye. Exp Eye Res 2011;93:586–591
   PubMedGoogle Scholar
• Inomata H, Bill A, Smelser GK. Unconventional routes of aqueous humor outflow in cynomolgus monkey (Macaca Irus). Am J Ophthalmol 1972;73:893–907
   PubMed Web of Science ®Google Scholar
• Kaufman PL, Crawford K, Gabelt BT. The effects of prostaglandins on aqueous humor dynamics. In: Kooner KS, Zimmerman TJ, editors. New Ophthalmic Drugs Ophthalmol Clin North Am: Saunders; 1989. pp. 141–150
   Google Scholar
• Di Girolamo N, Verma MJ, McCluskey PJ, Lloyd A, Wakefield D. Increased matrix metalloproteinases in the aqeuous humor of patients and experimental animals with uveitis. Curr Eye Res 1996;15:1060–1068
   PubMed Web of Science ®Google Scholar
• Toris CB, Pederson JE. Aqueous humor dynamics in experimental iridocyclitis. Invest Ophthalmol Vis Sci 1987;28:477–481
   PubMed Web of Science ®Google Scholar
• Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992;263:F181–F191
   PubMed Web of Science ®Google Scholar
• Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005;1404:598–606
   Google Scholar
• Cheng L, Sapieha P, Kittlerova P, Hauswirth WW, Di Polo A. TrkB gene transfer protects retinal ganglion cells from axotomy-induced death in vivo. J Neurosci 2002;2210:3977–3986
   Google Scholar
• Martin KR, Quigley HA, Zack DJ, Levkovitch-Verbin H, Kielczewski J, Valenta D, et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci 2003;4410:4357–4365
   Google Scholar
• Buie LK, Rasmussen CA, Porterfield EC, Ramgolam VS, Choi VW, Markovic-Plese S, et al. Self-complementary AAV virus (scAAV), safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys. Invest Ophthalmol Vis Sci 2010;51:236–248
   PubMed Web of Science ®Google Scholar
• Borrás T, Gabelt BT, Klintworth GK, Peterson JC, Kaufman PL. Non-invasive observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye in vivo. J Gene Med 2001;3:437–449
   PubMed Web of Science ®Google Scholar
• Liu X, Brandt CR, Gabelt BT, Kaufman PL. Herpes Simplex virus mediated gene transfer to primate ocular tissues. Exp Eye Res 1999;69:385–395
   PubMed Web of Science ®Google Scholar
• Barraza RA, McLaren JW, Poeschla EM. Prostaglandin pathway gene therapy for sustained reduction of intraocular pressure. Mol Ther 2010;183:491–501
   Google Scholar
• Borrás T, Brandt CR, Nickells RW, Ritch R. Gene therapy for glaucoma: treating a multifaceted, chronic disease. Invest Ophthalmol Vis Sci 2002;43:2513–2518
   PubMed Web of Science ®Google Scholar
• Borrás T. Recent developments in ocular gene therapy. Exp Eye Res 2003;76:643–652
   PubMed Web of Science ®Google Scholar
• Balaggan KS, Ali RR. Ocular gene delivery using lentiviral vectors. Gene Ther 2012;192:145–153
   Google Scholar
• Poeschla E, Wong-Staal F, Looney DJ. Efficient transduction of nondividing cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998;4:354–357
   PubMed Web of Science ®Google Scholar
• Miyazawa T, Kawaguchi Y, Kohmoto M, Sakuragi J, Adachi A, Fukasawa M, et al. Production of feline immunodeficiency virus in a feline and non-feline non-lymphoid cell lines by transfection of an infections molecular clone. J Gen Virol 1992;73:1543–1546
   PubMedGoogle Scholar
• Sparger EE, Shacklett BL, Renshaw-Gegg L, Barry PA, Pedersen NC, Elder JH, et al. Regulation of gene expression directed by the long terminal repeat of the feline immunodeficiency virus. Virology 1992;187:165–177
   PubMedGoogle Scholar
• Tomonaga K, Miyazawa T, Kawaguchi Y, Kohmoto M, Inoshima Y, Mikami T. Comparison of the Rev transactivation of feline immunodeficiency virus in feline and non-feline cell lines. J Vet Med Sci 1994;56:199–201
   PubMedGoogle Scholar
• Loewen N, Fautsch MP, Peretz M, Bahler CK, Cameron JD, Johnson DH, et al. Genetic modification of human trabecular meshwork wiith lentiviral vectors. Hum Gene Ther 2001;1217:2109–2119
   Google Scholar
• Loewen N, Bahler C, Teo W-L, Whitwam T, Peretz M, Xu R, et al. Preservation of aqueous outflow facility after second-generation FIV vector-mediated expression of marker genes in anterior segments of human eyes. Invest Ophthalmol Vis Sci 2002;43:3686–3690
   PubMed Web of Science ®Google Scholar
• Hudde T, Apitz J, Bordes-Alonso R, Heise K, Johnson KT, Steuhl KP, et al. Gene transfer to trabecular meshwork endothelium via direct injection into the Schlemm canal and in vivo toxicity study. Curr Eye Res 2005;30:1051–1059
   PubMed Web of Science ®Google Scholar
• Loewen N, Fautsch MP, Teo W-L, Bahler CK, Johnson DH, Poeschla EM. Long-term, targeted genetic modification of the aqueous humor outflow tract coupled with noninvasive imaging of gene expression in vivo. Invest Ophthalmol Vis Sci 2004;45:3091–3098
   PubMed Web of Science ®Google Scholar
• Khare PD, Loewen N, Teo W, Barraza RA, Saenz DT, Johnson DH, et al. Durable, safe, multi-gene lentiviral vector expression in feline trabecular meshwork. Mol Ther 2008;161:97–106
   Google Scholar
• Barraza RA, Rasmussen CA, Loewen N, Cameron JD, Gabelt BT, Teo W-L, et al. Prolonged transgene expression with lentiviral vectors in the aqueous humor outflow pathway of non-human primates. Human Gene Ther 2009;20:191–200
   PubMed Web of Science ®Google Scholar
• Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145–182
   PubMed Web of Science ®Google Scholar
• Watanabe K, Fujii Y, Ohkubo H, Kuramitsu S, Kagamiyama H, Nakanishi S, et al. Expression of bovine lung prostaglandin F synthase in Escherichia coli. Bioch Biophys Res Commun 1991;1811:272–278
   Google Scholar
• Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, et al. DNA deamination medicates innate immunity to retroviral infection. Cell 2003;1136:803–809
   Google Scholar
• Yap MW, Nisole S, Lynch C, Stoye JP. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci USA 2004;10129:10786–10791
   Google Scholar
• Sanz-Ramos M, Stoye JP. Capsid-binding retrovirus restriction factors: discovery, restriction specificity and implications for the development of novel therapeutics. J Gen Virol 2013;94:2587–2598
   PubMed Web of Science ®Google Scholar
• Zielonka J, Münk C. Cellular restriction factors of feline immunodeficiency virus. Viruses 2011;310:1986–2005
   Google Scholar
• Harris RS, Hultquist JF, Evans DT. The restriction factors of human immunodeficiency virus. J Biol Chem 2012;28749:40875–40883
   Google Scholar
• Wang Y, Shao Q, Yu X, Kong W, Hildreth JE, Liu B. N-terminal hemagglutinin tag renders lysine-deficient APOBEC3G resistant to HIV-1 Vif-induced degradation by reduced polyubiquitination. J Virol 2011;859:4510–4519
   Google Scholar
• Battivelli E, Migraine J, Lecossier D, Matsuoka S, Perez-Bercoff D, Saragosti S, et al. Modulation of TRIM5alpha activity in human cells by alternatively spliced TRIM5 isoforms. J Virol 2011;8515:7828–7835
   Google Scholar
• Cocka LJ, Bates P. Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog 2012;89:e1002931
   Google Scholar
• Liberatore RA, Bieniasz PD. Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci USA 2011;10844:18097–18101
   Google Scholar
• Boone LR, Innes CL, Heitman CK. Abrogation of Fv-1 restriction by genome-deficient virions produced by a retrovirus packaging cell line. J Virol 1990;647:3376–3381
   Google Scholar
• Löser P, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J Virol 1998;721:180–190
   Google Scholar
• Brandt CR, Imesch P, Spencer BI, Eliassi-Rad B, Syed NA, Untawale S, et al. The herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease. Arch Virol 1997;142:883–896
   PubMedGoogle Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;115:373–384
   Google Scholar
• Rathinam VA, Fitzgerald KA. Innate immune sensing of DNA viruses. Virology 2011;4112:153–162
   Google Scholar
• Bazan NG, Allan G. Signal transduction and gene expression in the eye: a contemporary view of the pro-inflammatory, anti-inflammatory and modulatory roles of prostaglandins and other bioactive lipids. Surv Ophthalmol 1997;41:S23–S34
   PubMed Web of Science ®Google Scholar
• Bito LZ. Prostaglandins and other Eicosanoids:their ocular transport, pharmacokinetics, and therapeutic effects. Trans Ophthalmol Soc U K 1986;105:162–170
   PubMedGoogle Scholar
• Kaufman PL, Gabelt BT. Presbyopia, prostaglandins and primary open angle glaucoma. In: Krieglstein GK, editor. Glaucoma update V proceedings of the Symposium of the Glaucoma Society of the International Congress of Ophthalmology in Quebec City, June 1994. New York-Berlin: Springer-Verlag; 1995. pp. 224–41
   Google Scholar
• Peterson JC, Rasmussen CA, Kaufman PL. Green fluorescent protein imaging in a model for proposed gene therapy in glaucoma. J Ophthalmic Photogr 2007;29:106–111
   Google Scholar
• Saenz DT, Barraza R, Loewen N, Teo W, Poeschla EM. Production and use of feline immunodeficiency virus-based lentiviral vectors. In: Friedman T, Rossi J, editors. Gene Transfer: Delivery and Expression of DNA and RNA. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2007. pp. 57–73
   Google Scholar